Business UpdateJun 29, 2026, 08:01 AM
Elicio Therapeutics Added to Russell 2000 & 3000 Indexes
AI Summary
Elicio Therapeutics, Inc. announced its inclusion in the Russell 2000® and Russell 3000® Indexes, effective June 26, 2026. This milestone is expected to broaden the company's visibility with institutional investors and reflects growing recognition of its progress. Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for KRAS-driven cancers, with its lead product candidate ELI-002 7P currently in development.
Key Highlights
- Elicio Therapeutics added to Russell 2000® and Russell 3000® Indexes.
- Inclusion became effective after U.S. market close on June 26, 2026.
- Russell 3000® Index tracks the largest 3,000 publicly traded U.S. companies.
- Russell 2000® Index measures small-cap stocks, representing ~10% of U.S. equity market.
- Approximately $12.2 trillion in assets are benchmarked to Russell US indexes.
- CEO Robert Connelly stated inclusion broadens visibility with institutional investors.
- Company continues to advance its ELI-002 7P program for KRAS-driven cancers.
Price Impact
More from ELTX